AEON Biopharma receives positive end-of-Phase 2 meeting with FDA for ABP-450 migraine programs, aligning on Phase 3 trial design and endpoints.
AEON Biopharma reports key milestones for its ABP-450 episodic and chronic migraine programs, including a positive end-of-Phase 2 meeting with the FDA, leading to alignment on Phase 3 trial design and endpoints. AEON completed enrollment in its Phase 2 study of ABP-450 for chronic migraine, with interim analysis results expected in Q2 2024. The company also entered a $15M private placement with strategic partner Daewoong Pharmaceutical.
March 29, 2024
3 Articles